2nd Quarter - Report

SOCIETY FOR MATERNAL-FETAL MEDICINE for SOCIETY FOR MATERNAL-FETAL MEDICINE

Firm
Client
Income
—
Expenses
$10,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Increases in funding in FY 2024 and FY 2025 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.

LobbyistCovered position, as disclosed
REBECCA ABBOTT New —

Contacted: Agency for Healthcare Research & Quality (AHRQ); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; SENATE; Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA)

Health Issues HCR

maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)

LobbyistCovered position, as disclosed
REBECCA ABBOTT New —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); SENATE; Health Resources & Services Administration (HRSA)

Bills named: H.R. 1117 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.